AtaiBeckley is a technology company.
AtaiBeckley has raised $322.0M across 4 funding rounds.
AtaiBeckley has raised $322.0M in total across 4 funding rounds.
AtaiBeckley is a clinical-stage biopharmaceutical company, not a technology company in the traditional software sense, focused on developing effective, rapid-acting, and convenient treatments for mental health conditions.[1][2] It addresses the massive unmet need in mental health, where over one billion people worldwide live with such conditions, most lack access to effective care, and global economic costs are projected to hit $5 trillion by 2030.[1] The company serves patients with limited treatment options through a pipeline of patient-first, evidence-based therapies, particularly leveraging psychedelic-inspired candidates, and recently achieved a milestone by being added to the Nasdaq Biotechnology Index (NBI).[2]
Formed via a $390 million merger of two psychedelic medicine pioneers, AtaiBeckley combines expertise in drug development, healthcare, and commercialization to transform outcomes in this space.[1][3] Its growth momentum includes a robust pipeline targeting high-need areas and public market recognition, positioning it for scaled impact.[2][3]
AtaiBeckley emerged from a landmark $390 million merger between atai Life Sciences and Beckley Psytech, two pioneers in psychedelic medicines, which completed recently to consolidate their pipelines for mental health treatments.[3] This union builds on atai's model of incubating and advancing novel therapies and Beckley's focus on rapid-acting psychedelics, creating a unified entity with deep expertise in clinical-stage biopharma.[1][3]
The idea stems from the urgent need to overhaul mental health care, where traditional options fall short for over a billion affected individuals.[1] Early traction came from the merging entities' parallel advancements in psychedelic candidates, culminating in this deal to accelerate development and commercialization under a shared mission.[3] Key leadership includes a diverse team of drug development and healthcare experts driving the effort.[1]
AtaiBeckley rides the surging wave of psychedelic and neuroscience biotech, harnessing repurposed compounds for mental health amid rising awareness of conditions affecting one billion people.[1][3] Timing is ideal as regulatory shifts, post-pandemic mental health crises, and economic projections ($5 trillion by 2030) create tailwinds for innovative therapies over legacy treatments.[1]
Market forces like limited access to care favor its rapid-acting pipeline, influencing the ecosystem by validating psychedelics in clinical stages and accelerating mergers in the space.[3] As a Nasdaq-listed player, it bridges biotech with broader tech-health intersections, drawing investment into evidence-based mental health innovation.[2]
AtaiBeckley is poised to advance its pipeline through key clinical readouts and potential approvals, capitalizing on merger synergies for faster commercialization.[3] Trends like AI-aided drug discovery, psychedelic normalization, and global mental health funding will shape its path, potentially expanding into new therapeutic areas.[1]
Its influence may evolve from pipeline consolidator to market leader, redefining treatments and inspiring ecosystem-wide breakthroughs—transforming the one-billion-person challenge into scalable solutions, as its mission promises.[1][2]
AtaiBeckley has raised $322.0M in total across 4 funding rounds.
AtaiBeckley's investors include Ambridge Capital, Brkfst Club, Calm/Storm Ventures, DN Capital, Endeavor Venture Funds, FJ Labs, Founders Fund, Future Ventures, Negev Capital, Presight Capital, PsyMed Ventures, Raine Ventures.
AtaiBeckley has raised $322.0M across 4 funding rounds. Most recently, it raised $160.0M Series D in March 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Mar 1, 2021 | $160.0M Series D | Ambridge Capital, Brkfst Club, Calm/Storm Ventures, DN Capital, Endeavor Venture Funds, FJ Labs, Founders Fund, Future Ventures, Negev Capital, Presight Capital, PsyMed Ventures, Raine Ventures, Gil Penchina, Thiel Capital, What If Ventures, Akshay Sriprasad, Eytan Elbaz | |
| Nov 1, 2020 | $93.0M Series C | Calm/Storm Ventures, Endeavor Venture Funds, Founders Fund, Future Ventures, Negev Capital, Presight Capital, PsyMed Ventures, Thiel Capital, What If Ventures, Akshay Sriprasad | |
| Feb 1, 2019 | $43.0M Series B | Aglae Ventures | |
| Oct 1, 2018 | $26.0M Series A | Adjacent, Archetype, Asylum Ventures, Galaxy Digital, Initialized Capital, Kleiner Perkins, Otherwise Fund |